SBI Securities Co. Ltd. Acquires 48,309 Shares of Biogen Inc. $BIIB

SBI Securities Co. Ltd. grew its holdings in Biogen Inc. (NASDAQ:BIIB) by 3,284.1% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 49,780 shares of the biotechnology company’s stock after acquiring an additional 48,309 shares during the period. SBI Securities Co. Ltd.’s holdings in Biogen were worth $11,244,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of Biogen in the 2nd quarter worth about $3,453,878,000. Primecap Management Co. CA purchased a new stake in shares of Biogen during the 2nd quarter valued at about $3,274,304,000. Wellington Management Group LLP lifted its holdings in shares of Biogen by 5.3% in the 2nd quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock valued at $673,560,000 after acquiring an additional 155,828 shares during the last quarter. Amundi lifted its holdings in shares of Biogen by 91.8% in the 2nd quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock valued at $327,727,000 after acquiring an additional 726,004 shares during the last quarter. Finally, Legal & General Group Plc bought a new position in shares of Biogen in the 2nd quarter valued at about $322,640,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Trading Up 5.3%

Shares of BIIB opened at $253.84 on Friday. Biogen Inc. has a 1-year low of $138.00 and a 1-year high of $254.41. The company has a 50-day moving average of $222.78 and a 200 day moving average of $205.73. The firm has a market capitalization of $37.50 billion, a price-to-earnings ratio of 44.93, a PEG ratio of 2.68 and a beta of 0.09. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.94 by $0.66. The company had revenue of $2.74 billion during the quarter, compared to analysts’ expectations of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The firm’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the previous year, the company earned $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, research analysts expect that Biogen Inc. will post 12.31 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on BIIB shares. Stifel Nicolaus set a $242.00 price target on Biogen in a research report on Thursday, September 10th. HSBC upped their price objective on Biogen from $165.00 to $175.00 and gave the company a “reduce” rating in a research report on Thursday, September 10th. Piper Sandler restated an “overweight” rating and set a $245.00 price objective (up from $225.00) on shares of Biogen in a research report on Thursday, September 3rd. BMO Capital Markets reaffirmed a “market perform” rating and issued a $220.00 price objective on shares of Biogen in a research note on Monday, October 12th. Finally, Needham & Company LLC lifted their target price on Biogen from $255.00 to $256.00 and gave the stock a “buy” rating in a report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $241.89.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Wells Fargo raised its price target on Biogen, adding to a series of upward analyst revisions and reinforcing optimism about the company’s outlook. Biogen Stock Gets Price Target Boost from Wells Fargo
• Positive Sentiment: Bank of America increased its Biogen price target to $244 from $219. Although the firm maintained a Neutral rating, the revision reflects improved expectations as analysts update their models ahead of earnings. Biogen on BofA Price Target Hike
• Positive Sentiment: Several previews suggest Biogen could exceed third-quarter earnings estimates, supported by favorable analyst expectations and the potential for continued progress across its late-stage drug pipeline. Biogen Expected to Beat Earnings Estimates
• Neutral Sentiment: Wedbush kept a Hold rating on Biogen, indicating that valuation and near-term catalysts may already be reflected in the share price. Wedbush Remains a Hold on Biogen
• Negative Sentiment: Bank of America’s $244 target remains below the stock’s recent trading level, implying limited upside or potential downside despite the target increase. Analysts also characterize the upcoming quarter as relatively quiet, and earnings previews warn that disappointment remains possible.

Biogen Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.